Advancing Pharmaceutical Processes Through Real-Time Analytics

	Biotechnology
	The latest Biotechnology news from AZoNetwork

From early development through manufacturing, reliable analytical workflows can provide deeper insight into pharmaceutical processes. This eBook explores technologies and strategies that support material characterization, real-time process understanding, and quality control, helping scientists make informed decisions throughout pharmaceutical development.

Download the Full eBook

Modern LC-MS bioanalysis across therapeutic modalities

Bioanalysis continues to evolve as therapeutic modalities become increasingly complex. Discover expert insights, real-world case studies, and proven LC-MS strategies for peptides, proteins, oligonucleotides, targeted protein degraders, and small molecules. Learn how leading laboratories generate confident results and accelerate decision-making across modern bioanalytical workflows.

Discover More Here

Rentosertib shifts multiple proteomic aging clocks toward younger age profiles in IPF trial

Researchers applied six proteomic aging clocks to serum samples from a phase 2a trial of rentosertib in people with idiopathic pulmonary fibrosis and found treatment-associated shifts toward younger predicted biological-age profiles, particularly with the 30 mg twice-daily regimen.

	Nanomaterials Offer Multiple Routes to Protect Healthy Tissue From Radiation Damage A comprehensive review examined how nanomaterials could protect healthy tissues from radiation damage through targeted drug delivery, reactive oxygen species scavenging, anti-inflammatory activity, and physical radiation shielding.

	Aston University partners with Labskin to grow more realistic laboratory-grown human skin Aston University has joined forces with Yorkshire-based biotechnology company Labskin to develop more realistic laboratory-grown human skin that includes immune cells.

	Generative AI-driven drug Rentosertib enters Phase III trial for idiopathic pulmonary fibrosis Insilico Medicine, a clinical-stage biotechnology company powered by generative AI, today announced that it has dosed the first patient with Rentosertib (known as ISM001-055 / INS018_055) in GENESIS-IPF-3, a Phase III clinical trial (NCT07687459, CTR20262475) at Peking Union Medical College Hospital, while Shanghai Pulmonary Hospital has also enrolled its first patient on the same day.

	Diaceutics launches Precision for All Strategic Collaboration at Fierce Pharma Week 2026 Intelligence and engagement company, Diaceutics, is bringing together senior voices from across the biopharmaceutical industry at the Precision for All Strategic Collaboration, launching at Fierce Pharma Week 2026.

	EpilepsyGTx and Viralgen collaborate to advance AAV gene therapy program for epilepsy ahead of first-in-human trial EpilepsyGTx, a biotechnology company developing gene therapies for refractory epilepsy, and Viralgen, a leading contract development and manufacturing organization (CDMO) specializing in recombinant adeno-associated virus (AAV) gene therapies, today announced a partnership to support production of EpilepsyGTx's lead investigational gene therapy program targeting patients with focal refractory epilepsy (FRE), EPY201, ahead of first-in-human...

	Characterizing subvisible particles in biopharmaceuticals Explore the newest analytical approaches for identifying subvisible particles in biologic drug formulations.

How would you rate today's newsletter?

Stay updated with the latest in health and medical news! Follow News‑Medical.net on Google News for real‑time updates. Click here to follow us now.

Why did you receive this email?
You are receiving this email because you subscribed to updates from AZoNetwork UK Ltd. on one of our websites and requested to be notified of additional information.

Unsubscribe or Update Notification Preferences

Contact | About | Privacy Policy

- - - - - -

Registered Address:
AZoNetwork UK Ltd.,

Manchester | Sydney

Copyright © 2000-2026